API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 2 sources · 14 days · First seen · Last updated

Semaglutide market developments in Brazil and Spain

Overview

Developments regarding semaglutide treatments have emerged in Brazil and Spain. In Brazil, Dr Reddy’s Laboratories secured marketing authorization from the National Health Surveillance Agency (ANVISA) to sell a generic version of the medication in 2 mg and 4 mg doses. This follows a previous regulatory denial in April. The company intends to launch the product in collaboration with Aché to target the Brazilian diabetes market.

In Spain, Novo Nordisk introduced a new 2 mg weekly dose of Ozempic. This dosage is funded by the Spanish National Health System for treating adults with type 2 diabetes. Medical specialists noted that the higher dose provides increased efficacy in glycemic control and weight management for patients who do not meet metabolic targets on the 1 mg dose.

Entities

Novo Nordisk · Brazil · Spain · Aché · Dr Reddy’s Laboratories

Timeline

  1. [HEALTH] 2 sources
    Novo Nordisk launches 2 mg Ozempic dose in Spain

    A new 2 mg weekly dose of Ozempic is now available in Spain for adults with type 2 diabetes, offering improved glycemic control and weight reduction compared to the 1 mg dose.

  2. [BUSINESS] 5 sources
    Dr Reddy’s Laboratories receives Brazil approval for generic Ozempic

    Dr Reddy’s Laboratories has obtained regulatory approval from Brazil’s ANVISA to market a generic version of semaglutide for type 2 diabetes treatment.

Sources

immedicohospitalario.es · lacronicadebadajoz.elperiodicoextremadura.com